Hospital Universitario Austral -HUA-
Es un Hospital Universitario que se empeña en brindar la más alta calidad y seguridad en los cuidados de salud, situando las necesidades del paciente y su familia en el centro de nuestra atención, integrando la asistencia con la educación y la investigación biomédica y que busca vivir y trasmitir valores humanos y cristianos.
https://riu.austral.edu.ar/handle/123456789/703
2024-03-29T06:36:11Z
2024-03-29T06:36:11Z
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
Mendizabal, Manuel.
Piñero, Federico.
Ridruejo, Ezequiel.
Et al.
https://riu.austral.edu.ar/handle/123456789/3044
2024-03-25T23:49:11Z
2020-10-01T00:00:00Z
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
Mendizabal, Manuel.; Piñero, Federico.; Ridruejo, Ezequiel.; Et al.
Abstract
Background & aims: Little is known about how a sustained virologic response (SVR) to treatment of hepatitis C virus infection with direct-acting antivirals (DAAs) affects patient mortality and development of new liver-related events. We aimed to evaluate the incidence of disease progression in patients treated with DAAs.
Methods: We performed a prospective multicenter cohort study of 1760 patients who received DAA treatment at 23 hospitals in Latin America, from May 1, 2016, through November 21, 2019. We excluded patients with a history of liver decompensation, hepatocellular carcinoma (HCC), or solid-organ transplantation. Disease progression after initiation of DAA therapy included any of the following new events: liver decompensation, HCC, liver transplantation, or death. Evaluation of variables associated with the primary outcome was conducted using a time-dependent Cox proportional hazards models.
Results: During a median follow-up period of 26.2 months (interquartile range, 15.3-37.5 mo), the overall cumulative incidence of disease progression was 4.1% (95% CI, 3.2%-5.1%), and after SVR assessment was 3.6% (95% CI, 2.7%-4.7%). Baseline variables associated with disease progression were advanced liver fibrosis (hazard ratio [HR], 3.4; 95% CI, 1.2-9.6), clinically significant portal hypertension (HR, 2.1; 95% CI, 1.2-3.8), and level of albumin less than 3.5 mg/dL (HR, 4.1; 95% CI, 2.3-7.6), adjusted for SVR achievement as a time covariable. Attaining an SVR reduced the risk of liver decompensation (HR, 0.3; 95% CI, 0.1-0.8; P = .016) and de novo HCC (HR, 0.2; 95% CI, 0.1%-0.8%; P = .02) in the overall cohort.
Conclusions: Treatment of hepatitis C virus infection with DAAs significantly reduces the risk of new liver-related complications and should be offered to all patients, regardless of disease stage. Clinicaltrials.gov: NCT03775798.
Keywords: Cancer; Long-Term; Survival; Viral Infection.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
PubMed Disclaimer
Disponible en: https://www.clinicalkey.es/#!/content/playContent/1-s2.0-S1542356520302639?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1542356520302639%3Fshowall%3Dtrue&referrer=https:%2F%2Fpubmed.ncbi.nlm.nih.gov%2F
2020-10-01T00:00:00Z
Prenatal genetic considerations in congenital ventriculomegaly and hydrocephalus.
Etchegaray, Adolfo.
Juarez-Peñalva, Sofia.
Petracchi, Florencia.
Et al.
https://riu.austral.edu.ar/handle/123456789/3041
2024-03-25T23:49:04Z
2020-08-01T00:00:00Z
Prenatal genetic considerations in congenital ventriculomegaly and hydrocephalus.
Etchegaray, Adolfo.; Juarez-Peñalva, Sofia.; Petracchi, Florencia.; Et al.
Abstract
Background: Fetal ventriculomegaly (VM) is a frequent finding in prenatal ultrasound. Rather than a proper diagnosis, VM is a sonographic sign, making prenatal counseling a complex and challenging undertaking. VM can range from severe pathologic processes leading to severe neurodevelopmental delay to normal variants.
Discussion: A growing number of genetic conditions with different pathophysiological mechanisms, inheritance patterns, and long-term prognosis have been associated both to isolated and complex fetal VM. These include chromosomal abnormalities, copy number variants, and several single gene diseases. In this review, we describe some of the most common genetic conditions associated with fetal VM and provide a simplified diagnostic workflow for the clinician.
Keywords: Congenital hydrocephalus; Fetal ventriculomegaly; Prenatal diagnosis; Prenatal genetic testing.
PubMed Disclaimer
Disponible en: https://link.springer.com/article/10.1007/s00381-020-04526-5
2020-08-01T00:00:00Z
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, Federico.
Dirchwolf, Melisa.
Pessôa, Mário.
https://riu.austral.edu.ar/handle/123456789/2805
2024-03-25T23:40:16Z
2020-06-01T00:00:00Z
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, Federico.; Dirchwolf, Melisa.; Pessôa, Mário.
Abstract
Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and treatment strategies to improve the prognosis of this malignancy. The identification of useful biomarkers for surveillance and early HCC diagnosis is still deficient, with available serum biomarkers showing low sensitivity and heterogeneous specificity despite different cut-off points, even when assessed longitudinally, or with a combination of serum biomarkers. In contrast, HCC biomarkers used for prognostic (when associated with clinical outcomes) or predictive purposes (when associated with treatment response) may have an increased clinical role in the near future. Furthermore, some serum biomarkers are already implicated as a treatment selection tool, whether to provide access to certain therapies or to assess clinical benefit after treatment. In the present review we will discuss the clinical utility and foreseen future of HCC biomarkers implicated in surveillance, diagnosis, prognosis, and post-treatment assessment.
Keywords: biological; liver cancer; markers.
PubMed Disclaimer
Disponible en: https://www.mdpi.com/2073-4409/9/6/1370
2020-06-01T00:00:00Z
Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer
Galizzi, Lucrecia.
García, Ximena.
Elía, Andrés.
Et al.
https://riu.austral.edu.ar/handle/123456789/2803
2024-03-25T23:40:09Z
2020-02-01T00:00:00Z
Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer
Galizzi, Lucrecia.; García, Ximena.; Elía, Andrés.; Et al.
Abstract
Purpose: Expression of estrogen receptor alpha (ER) and/or progesterone receptor (PR) defines luminal breast cancer. Even though androgen (AR) and glucocorticoid receptors (GR) are highly expressed in luminal breast cancers, prognostic value remains uncertain and concomitant expression of these four hormone receptors is still unexplored.
Methods: Here, we evaluated ER, PR, AR, and GR expression, using immunohistochemistry, in a cohort of 169 breast cancer patients and correlated these findings with clinical and pathological parameters.
Results: We found that AR is more frequently expressed and at higher levels in the ER+PR- subset compared to ER+PR+ tumors. There were no significant differences in GR expression between tumor subsets. Moreover, most luminal tumors also expressed either AR or GR and most basal tumors were also negative for AR and GR.
Conclusion: These data suggest that targeting AR in ER+PR- tumors may represent a promising therapeutic alternative in hormonal refractory tumors.
Keywords: Androgen receptor; Breast cancer; Human samples; Luminal B subtype.
PubMed Disclaimer
Disponible en: https://link.springer.com/article/10.1007/s10549-020-05527-3
2020-02-01T00:00:00Z